Emcure Pharmaceuticals Limited has informed the Exchange about Transcript
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals filed the transcript of its Q1 FY26 earnings call held on August 7, 2025. Revenue grew 15.7% year-on-year to INR 2,101 crores, driven by 9.4% domestic growth (INR 995 cr) and 22% international growth (INR 1,106 cr). EBITDA rose 20% to INR 404 crores with margins at 19.2%, while profit after tax jumped 41% to INR 215 crores, the company's highest ever quarterly profit. Management unveiled a 5-year vision targeting 2% above-industry growth and 300-400 basis points of margin expansion (to 23-24% EBITDA) driven by productivity, product mix, and scaling of new businesses like Derma and Consumer Wellness. Recent acquisitions (Manx product portfolio and Zuventus minority stake) added to debt, pushing the zero-debt target out by 1-1.5 years from INR 700 crores currently. Key pipeline updates include Semaglutide filing in Canada, Asparaginase and Bevacizumab submissions, and ramp-up of Liposomal Amphotericin B and Tenecteplase in international markets. The company highlighted that US tariff concerns have minimal impact given less than 3% US exposure.
Strong quarterly performance with broad-based growth across domestic and international markets reinforces the growth story. Explicit margin expansion roadmap (150 bps in FY26 alone) and clear 5-year targets are positive signals for investors, though near-term debt reduction is delayed by recent M&A. Low US exposure (<3%) provides insulation from tariff headwinds.